A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

Multi-country Non-interventional Study on the Effectiveness of Empagliflozin in Adult Patients With Type 2 Diabetes in Europe and Asia.

Non-interventional, multi-country cohort study using existing data and including adults (≥18 years) with a diagnosis of Type 2 diabetes mellitus.

Inclusion Criteria:

• Dispensation or any other record of empagliflozin, any SGLT-2 inhibitor, or any DPP-4 inhibitor use during the study period
• No dispensation or any other record of any other SGLT-2 inhibitor or DPP-4 inhibitor use during the preceding 12 months including at index date
• Having a diagnosis of T2DM before the index date, based on ICD-10 codes or other available data

Exclusion Criteria:

• Aged <18 years on the first dispensation date or date of the first record of empagliflozin, any SGLT-2 inhibitor or any DPP-4 inhibitor use
• Type 1 diabetes mellitus
• Secondary diabetes
• Gestational diabetes
• Having a diagnosis of ESRD during the 12 months before the index date
• <12 months of available data before the index date, and/or no complete history of drug dispensations/other records of the drug use during this period
• Missing or ambiguous data on age or sex